by B2i | May 14, 2020 | Press Releases
Two fully funded research projects with top four animal health companies. Nonexclusive research license agreement with WuXi Biologics. Feasibility study with the University of Oslo on influenza vaccine. Engineered C1 cell lines to produce high levels of potential...
by B2i | Apr 30, 2020 | Press Releases
JUPITER, FL / April 30, 2020 / Dyadic International, Inc. (“Dyadic”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and...
by B2i | Mar 30, 2020 | Press Releases
New research license agreement with WuXi Biologics, a leading global CDMO Two new fully funded collaborations and one expanded collaboration signed in 2020, including the third fully funded collaboration with a top tier animal health company Six funded research...
by B2i | Mar 30, 2020 | Press Releases
JUPITER, FL / March 30, 2020 / Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development,...
by B2i | Mar 19, 2020 | Press Releases
NEW YORK, NY / March 19, 2020 / Dyadic International, Inc. (Nasdaq: DYAI) Dyadic’s Chief Financial Officer Ping Rawson will be presenting at this year’s New York City based Investor Summit on March 25th-26th. During the current climate of concern, The...
by B2i | Mar 18, 2020 | Press Releases
JUPITER, FL / March 18, 2020 / Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development,...
